Skip to main content
Fig. 5 | Journal of Experimental & Clinical Cancer Research

Fig. 5

From: An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment resistance of human pancreatic cancer

Fig. 5

FL118 targets both proliferative cancer cells and latent stem cell-like cancer cells: a, FL118-cisplatin combination enhances killing of PANC1 cells. Dead cells were determined by trypan blue exclusion. b, GFPcODC-positive cells survive 50-□M cisplatin for 4 days, evaluated with trypan blue exclusion assay. c, FL118-cisplatin kills GFPcODC positive (drug-resistant) cells (arrows). Phase-contrast and GFP imaging of cells were digitally taken. d, FL118-cisplatin combination reduces PANC1 spheroid cell number. *, P < 0.001. FL, FL118; T, time. e, Effects of FL118 on pancreatic cancer stem cell sphere formation. See detail in the method section. f, Colony formation of CD44 stem cell marker-positive pancreatic cancer cells. g, Quantitative data derived from the data shown in the Fig. 5f

Back to article page